search
Back to results

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
Japan
Study Type
Interventional
Intervention
AZD1656
Placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes mellitus, Japanese, phase 2, AZD1656, efficacy, dose regimen, pharmacokinetics

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • women of non-childbearing potential.
  • Provision of informed consent prior to any study specific procedures
  • Naïve T2DM patients with HbA1c ≥ 7.5% but ≤ 10% or T2DM Patients treated with one or two oral anti-hyperglycaemic agent(s) with HbA1c ≥ 7.5% but ≤ 9.5% at enrolment visit (Visit1)

Exclusion Criteria:

  • Clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, hepatic disease and haematological disease.
  • The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.
  • Participation in another clinical trial and/or intake of another investigational drug within the last 30 days prior to enrolment visit

Sites / Locations

  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

high

Middle

low

4

Arm Description

AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)

AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)

AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)

Outcomes

Primary Outcome Measures

Change in Haemoglobin A1c (HbA1c)

Secondary Outcome Measures

Change in Fasting Plasma Glucose (FPG)
Number of Responders in Terms of HbA1C ≤ 7%
Number of Responders in Terms of HbA1C ≤ 6.5%
Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C)
Percentage Change in High-density Lipoprotein Cholesterol (HDL-C)
Percentage Change in Triglycerides
Change in High-sensitivity C-reactive Protein (Hs-CRP)

Full Information

First Posted
June 10, 2010
Last Updated
July 24, 2012
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT01152385
Brief Title
Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
Official Title
A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
May 2010 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
May 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the effect on glucose control of 3 different AZD1656 dosing regimens with placebo in Japanese type 2 diabetes mellitus (T2DM) patients, as evaluated by the change in HbA1c from baseline to the end of treatment at 4 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes mellitus, Japanese, phase 2, AZD1656, efficacy, dose regimen, pharmacokinetics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
224 (Actual)

8. Arms, Groups, and Interventions

Arm Title
high
Arm Type
Experimental
Arm Description
AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
Arm Title
Middle
Arm Type
Experimental
Arm Description
AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
Arm Title
low
Arm Type
Experimental
Arm Description
AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
Arm Title
4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
AZD1656
Intervention Description
Oral tablet administered twice daily during 4 months
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
administered twice daily during 4 months
Primary Outcome Measure Information:
Title
Change in Haemoglobin A1c (HbA1c)
Time Frame
from baseline to 4 months
Secondary Outcome Measure Information:
Title
Change in Fasting Plasma Glucose (FPG)
Time Frame
from baseline to 4 months
Title
Number of Responders in Terms of HbA1C ≤ 7%
Time Frame
at 4th month
Title
Number of Responders in Terms of HbA1C ≤ 6.5%
Time Frame
at 4th month
Title
Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C)
Time Frame
from baseline to 4 months
Title
Percentage Change in High-density Lipoprotein Cholesterol (HDL-C)
Time Frame
from baseline to 4 months
Title
Percentage Change in Triglycerides
Time Frame
from baseline to 4 months
Title
Change in High-sensitivity C-reactive Protein (Hs-CRP)
Time Frame
from baseline to 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: women of non-childbearing potential. Provision of informed consent prior to any study specific procedures Naïve T2DM patients with HbA1c ≥ 7.5% but ≤ 10% or T2DM Patients treated with one or two oral anti-hyperglycaemic agent(s) with HbA1c ≥ 7.5% but ≤ 9.5% at enrolment visit (Visit1) Exclusion Criteria: Clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, hepatic disease and haematological disease. The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history. Participation in another clinical trial and/or intake of another investigational drug within the last 30 days prior to enrolment visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Leonsson-Zachrisson
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Osaka
Country
Japan
Facility Name
Research Site
City
Suita
Country
Japan
Facility Name
Research Site
City
Tokyo
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
23522182
Citation
Kiyosue A, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Oct;15(10):923-30. doi: 10.1111/dom.12100. Epub 2013 Apr 22.
Results Reference
derived

Learn more about this trial

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

We'll reach out to this number within 24 hrs